Corporate
-
Ibrutinib (IMBRUVICA®) HELIOS Interim Analysis Study Data Show Significant Reductions in Risk of Progression or Death in Patients with Previously-Treated Chronic Lymphocytic Leukemia
Phase 3 data (abstract LBA7005) featured in the official press program of the 51st annual meeting of the American Society of Clinical Oncology -
STELARA® Receives CHMP Positive Opinion For Treatment Of Adolescents With Moderate To Severe Psoriasis In Europe
STELARA Recommended for Approval in Paediatric Patients 12 Years and Older with Moderate to Severe Psoriasis -
SIMPONI® Receives CHMP Positive Opinion For Treatment Of Non-Radiographic Axial Spondyloarthritis In Europe
SIMPONI Recommended for Approval in Adult Patients with Severe Active Non-Radiographic Axial Spondyloarthritis -
New Real-World Data Show Adults with Type 2 Diabetes, Including Those Taking Multiple Diabetes Medications, Achieve Blood Glucose Treatment Goals After Using INVOKANA®(canagliflozin)
Findings Also Show Some Patients Discontinue Use of Other Blood-Glucose-Lowering Medications after Initiation of INVOKANA® -
Real-World Data Presented at American Geriatrics Society Meeting Show Consistent Safety of XARELTO® in Elderly Patients
Results Add to Findings from Ongoing Five-Year Post-Marketing Safety Program of XARELTO® Use in Clinical Practice -
Janssen to Showcase Data from Five Compounds Including Daratumumab and IMBRUVICA at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting
·Note: This release corresponds to ASCO abstracts LBA8512, 8587, 8590, TPS8609, TPS8608, LBA7005, 7012, TPS8599, TPS8601, 7024, TPS7095, TPS7096, 5005, 5047, 5053, 5014, 5028, TPS5071, TPS5084, 10503, 6537, TPS5606 -
-
Johnson & Johnson Expands IP Policy to Create Broad Access in 128 Countries for Development of New and Optimized HIV Medicine Formulations for Children Living with HIV
Expanded Policy will Increase Access for Darunavir Pediatric Formulations in 128 Resource-Limited Countries -
